Julius Bär (BAER VX) – FY revenue CHF 2.822bn (vs cons 2.956bn) / costs 1.691bn (vs cons 1.921bn) / EBIT 1.131bn (vs cons 977.2m) / net profit 868m (vs cons 652m) / net new money 361bn (vs cons 351.7bn) / cost/income ratio 59%. Outlook: sees up to 612m returned to shareholders – dividend of 1.00 and share buy back of up to 500m – plans 1:2 share split (BB)

NobelBiocare (NOBE VX) – FY sales EUR600.6m (vs cons 602.2m) / EBIT 204.2m (vs cons 206.6m) / net profit 158.1m (vs cons 162.4m). Outlook: sees 2007 revenue growth 23-25% in local currency – to pay CHF 4.25 dividend (vs CHF 3.50) – sees ’07 EBIT margin 34-35% (BB)

Syngenta (SYNN VX) – FY sales $8.046bn (vs cons 7.988bn) / EBITDA 1.54bn (vs cons 1.57bn) / net profit 872m (vs cons 892m) / new products sales rise 25% to 985m. Outlook: sees double-digit EPS growth through 2008 – sees 350m annual savings by 2011 – sees 2007 cash return around 800m (BB)

Micronas (MASN SW) – FY sales 812.5m (vs cons 807.3m) / operating loss – 17m (vs cons -25m) / net loss -1.6m (vs cons -13.7m). Outlook: no outlook given from the company but industry in consumer TV remains tough (BB)

Arpida (ARPN SW) – Arpida’s lead antibiotic Iclaprim is safe and well-tolerated in special populations with varying degrees of renal and hepatic impairment and obesity according to phase I study results published today (BB)

Bobst (BOBNN SW) – FY sales 1.604bn (vs cons 1.565bn). Outlook: company saw growth in the US and Asia-Pacific, whereas Europe and Africa/MiddleEast registered a decline in business activity – company sees order backlog level similar to year ago, expects higher ’06 net – companies long-term targets are EBIT margins of 7.5- 8.5% - earnings numbers out on March 28th (BB)